

Manufacturer price commitments for transitioned countries

April 2017

	Manufacturer	Commitment to transitioned countries
Pentavalent*	Janssen	◆ Access to price paid by Gavi through 2020
	Biological E	◆ Access to Gavi price through 2019
	Panacea	◆ 5 years price “freeze” post-graduation
Pneumococcal	GSK	<ul style="list-style-type: none"> ◆ 10 years price “freeze” post-transitioning out of Gavi’s financial support ◆ Access to AMC “tail price” (AMC supply significantly diminishes from ~2023)
	Pfizer	<ul style="list-style-type: none"> ◆ Access to AMC “tail price” (AMC supply significantly diminishes from ~2023) ◆ Access to \$3.10/dose price for 4-dose presentation through 2025
Rotavirus	GSK	◆ 10 years price “freeze” post-graduation
	Merck	◆ Extending current Gavi prices for 10 years (2016-2025) to Gavi-transitioned countries
HPV	GSK	◆ 10 years price “freeze” post-graduation
	Merck	◆ Extending current Gavi prices for 10 years (2016-2025) to Gavi-transitioned countries

Please note that Gavi is providing the information on this slide for informational purposes only. This information is meant for the convenience and benefit of countries and should not give a false sense of assurance that Gavi is “guaranteeing” prices, and that prices are determined for every single product and country. Rather, these manufacturer commitments are intended to help with country budgeting, but ultimately the decision lies with the individual manufacturer to offer a country a price matching its policies within a tender.